Regeneron Pharmaceuticals

Open: 808.29 Close: 808.47 Change: 0.18

Don't invest in Regeneron Pharmaceuticals Stock before reading this automated analysis produce by an AI.

How much time have you spent trying to decide whether investing in Regeneron Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. (regn) stock rises monday, still underperforms market - marketwatch.com regeneron.com. The biotech company manufactures Eylea, a drug to treat an eye disease.

Today's News

Regeneron Pharmaceuticals has on average historically risen by 32.4% based on the past 32 years of stock performance. Over the next 52 weeks, Regeneron has risen higher in 18 of those 32 years. Regeneron Pharmaceuticals Inc. (regn) news, articles, events & latest updates. Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of Regeneron pharmaceuticals in... Regeneron Pharmaceuticals (NASDAQ:REGN) is $ 808.46 last updated October 20, 2023 at 9:00 PM UTC. Q3 earnings are confirmed for Thursday, November 2, 20 23. There is no dividend information for Regeneron. Regeneron Pharmaceuticals inc. stock rises monday, still underperforms market - marketwatch.com regeneron.com. Recent FDA Approval Could Give Regenerons Top Line a Big Line. Regeneron Pharmaceuticals Inc (REGN) stock has gained 0.72% while the S&P 500 is down -0.95% as of 2:44 PM on Friday, Oct 20. Regeneron shares have a Bearish sentiment reading. The biotech company manufactures Eylea, a drug to treat an eye disease that affects an elderly.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

Are looking for the most relevant information about Regeneron Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Regeneron Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, rise, stock, year, Inc, share, and the most common words in the summary are: regeneron, pharmaceutical, stock, market, job, regn, inc, . One of the sentences in the summary was: The biotech company manufactures Eylea, a drug to treat an eye disease.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #stock #market #job #regn #inc.